Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic

por Díaz-Díaz, Judit, Ramirez, Clara Isabel, Ortiz-Pica, Marta, García-Yusta, Elena, Gómez-Estevez, Irene, Oreja-Guevara, Celia
Publicado 2021

Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients

por Díaz-Díaz, Judit, Ramirez, Clara Isabel, Ortiz-Pica, Marta, García-Yusta, Elena, Gómez-Estevez, Irene, Oreja-Guevara, Celia
Publicado 2021

Humoral Immune Response to SARS-CoV-2 Vaccination in MS Patients

por Oreja-Guevara, Celia, Díaz-Díaz, Judit, Suárez, Elda Alba, Gómez-Estévez, Irene, Sánchez, Johnny Quezada, Bullón-Sánchez, Cristina, Castro-Hernández, Matilde, Martinez-Pérez, Eduardo, Pérez, Silvia O´Connor, Muñoz, Elvira Baos
Publicado 2022

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

por Fernández-Velasco, José I., Monreal, Enric, Kuhle, Jens, Meca-Lallana, Virginia, Meca-Lallana, José, Izquierdo, Guillermo, Oreja-Guevara, Celia, Gascón-Giménez, Francisco, Sainz de la Maza, Susana, Walo-Delgado, Paulette E., Lapuente-Suanzes, Paloma, Maceski, Aleksandra, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Villarrubia, Noelia, Saiz, Albert, Blanco, Yolanda, Diaz-Pérez, Carolina, Valero-López, Gabriel, Diaz-Diaz, Judit, Aladro, Yolanda, Brieva, Luis, Íñiguez, Cristina, González-Suárez, Inés, Rodríguez de Antonio, Luis A, García-Domínguez, José M., Sabin, Julia, Llufriu, Sara, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M.
Publicado 2022